# Alpha-Gal-containing biologics

Kozak RP -- Ludger Ltd, Culham Science Centre, Oxfordshire, UK

Glycans containing the non-human epitope Gal $\alpha$ 1-3Gal (alpha-gal) can significantly decrease the clinical performance of therapeutic monoclonal antibodies (mAbs). The presence of Gal $\alpha$ 1-3Gal can affect the safety profile and lead to a potential adverse reaction and neutralisation of the drug by anti- $\alpha$ -galactose antibodies reducing therapeutic efficacy. Given the potential impact on patients, Gal $\alpha$ 1-3Gal are a high priority Glycosylation Critical Quality Attribute (GCQA) and drug developers must effectively optimise, measure and control the glycosylation of their products to limit Gal $\alpha$ 1-3Gal levels throughout the product life cycle.


Detecting and quantifying the amounts of Gal $\alpha$ 1-3Gal can be very difficult as these epitopes are often hidden by the complexity of the glycan profiles.

## How Ludger can help?

## 1. Ludger's Technology

Ludger offers a range of products for analysis of biologics containing alpha-gal epitope. This includes: (a) kits for N-glycan release; (b) kits for glycan labelling; (c) glycan clean-up systems; (d) buffers for HILIC-UPLC systems; (e) System Suitability Controls; (f) Process Controls and Reference Standards.

Ludger's strategy that mAb developers can use for detection and quantification of Gala1-3Gal bearing glycans:



#### Exoglycosidase Digestions followed by:


- HILIC-FLR-UPLC Or
- HILIC-FLR-UPLC-ESI-MS/MS (LC-MS/MS)
- Exoglycosidases:
  - Sialidase (removes α2-3,6,8 sialic acids)
  - Fucosidase (removes  $\alpha$ 1-2,3,4,6 fucose)
  - Beta Galactosidase (removes β1-4 galactose)
  - Alpha Galactosidase (specific for α-galactose)
  - Beta-N-acetylglucosaminidase (specific for GlcNAcs β-linked to mannose)
  - Mannosidase (removes α1-2,3,6 mannose) www.ludger.com/products/exoglycosidases
- Post-exoglycosidase Cleanup Plate: LC-PBM-96 (product guide)
- <u>Process Control</u> to assess the exoglycosidase digestions and analyses: Mixtures of N-glycans Common to mAb Samples: www.ludger.com/products/glycan-standards
- <u>Process Control</u> to assess the alpha galactosidase digestions and analyses: CAB-ALPHA-GAL-01 Native or fluorescently labelled glycan containing the Galα1-3Gal


If you require any further information on how we can help you select products, please contact us at: info@ludger.com

## 2. Ludger's Glycan Analysis Services

Our strategy is to offer a range of complementary analytical methods (e.g. HILIC-UPLC, exoglycosidase sequencing, HILIC-FLR-ESI-MS/MS) to answer questions about the structures of glycans on glycoproteins. The complexity of the analysis reflects the detail of the information required. We work closely with clients to design and execute appropriate glycoprofiling programmes and can work up to GMP standard. Our data and customised reports are used: (i) in process optimisation; (ii) to support regulatory submissions; (iii) for lot release of drug batches during biomanufacturing.

We can also transfer and validate these optimised glycoprofiling methods to your laboratories.





#### AUTHORIZED DISTRIBUTOR

MZ-Analysentechnik GmbH, Barcelona-Allee 17 • D-55129 Mainz Tel +49 6131 880 96-0, Fax +49 6131 880 96-20 e-mail: info@mz-at.de, www.mz-at.de

### WWW.ludger.com Ludger Ltd, Oxfordshire OX14 3EB UK